189 related articles for article (PubMed ID: 29972637)
1. NMR Measurements Reveal the Structural Basis of Transthyretin Destabilization by Pathogenic Mutations.
Leach BI; Zhang X; Kelly JW; Dyson HJ; Wright PE
Biochemistry; 2018 Jul; 57(30):4421-4430. PubMed ID: 29972637
[TBL] [Abstract][Full Text] [Related]
2. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
Hurshman Babbes AR; Powers ET; Kelly JW
Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic Mutations Induce Partial Structural Changes in the Native β-Sheet Structure of Transthyretin and Accelerate Aggregation.
Lim KH; Dasari AKR; Ma R; Hung I; Gan Z; Kelly JW; Fitzgerald MC
Biochemistry; 2017 Sep; 56(36):4808-4818. PubMed ID: 28820582
[TBL] [Abstract][Full Text] [Related]
4. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
Rodrigues JR; Simões CJ; Silva CG; Brito RM
Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
[TBL] [Abstract][Full Text] [Related]
5. Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease.
Ferrão-Gonzales AD; Palmieri L; Valory M; Silva JL; Lashuel H; Kelly JW; Foguel D
J Mol Biol; 2003 May; 328(4):963-74. PubMed ID: 12729768
[TBL] [Abstract][Full Text] [Related]
6. Fluorotryptophan Incorporation Modulates the Structure and Stability of Transthyretin in a Site-Specific Manner.
Sun X; Dyson HJ; Wright PE
Biochemistry; 2017 Oct; 56(41):5570-5581. PubMed ID: 28920433
[TBL] [Abstract][Full Text] [Related]
7. Kinetic analysis of the multistep aggregation pathway of human transthyretin.
Sun X; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2018 Jul; 115(27):E6201-E6208. PubMed ID: 29915031
[TBL] [Abstract][Full Text] [Related]
8. Structural Changes Associated with Transthyretin Misfolding and Amyloid Formation Revealed by Solution and Solid-State NMR.
Lim KH; Dasari AK; Hung I; Gan Z; Kelly JW; Wemmer DE
Biochemistry; 2016 Apr; 55(13):1941-4. PubMed ID: 26998642
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Lashuel HA; Lai Z; Kelly JW
Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
[TBL] [Abstract][Full Text] [Related]
10. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
[TBL] [Abstract][Full Text] [Related]
11. Thermodynamic Stability and Aggregation Kinetics of EF Helix and EF Loop Variants of Transthyretin.
Ferguson JA; Sun X; Dyson HJ; Wright PE
Biochemistry; 2021 Mar; 60(10):756-764. PubMed ID: 33645214
[TBL] [Abstract][Full Text] [Related]
12. The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin.
Morais-de-Sá E; Neto-Silva RM; Pereira PJ; Saraiva MJ; Damas AM
Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):512-9. PubMed ID: 16627944
[TBL] [Abstract][Full Text] [Related]
13. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity.
Hammarström P; Jiang X; Hurshman AR; Powers ET; Kelly JW
Proc Natl Acad Sci U S A; 2002 Dec; 99 Suppl 4(Suppl 4):16427-32. PubMed ID: 12351683
[TBL] [Abstract][Full Text] [Related]
14. Native state hydrogen exchange study of suppressor and pathogenic variants of transthyretin.
Liu K; Kelly JW; Wemmer DE
J Mol Biol; 2002 Jul; 320(4):821-32. PubMed ID: 12095258
[TBL] [Abstract][Full Text] [Related]
15. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?
Zhang Q; Kelly JW
Biochemistry; 2005 Jun; 44(25):9079-85. PubMed ID: 15966731
[TBL] [Abstract][Full Text] [Related]
16. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
[TBL] [Abstract][Full Text] [Related]
17. Why is Leu55-->Pro55 transthyretin variant the most amyloidogenic: insights from molecular dynamics simulations of transthyretin monomers.
Yang M; Lei M; Huo S
Protein Sci; 2003 Jun; 12(6):1222-31. PubMed ID: 12761393
[TBL] [Abstract][Full Text] [Related]
18. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.
Manral P; Reixach N
Biosci Rep; 2015 Jan; 35(1):. PubMed ID: 25395306
[TBL] [Abstract][Full Text] [Related]
19. Transthyretin variants with improved inhibition of β-amyloid aggregation.
Mangrolia P; Yang DT; Murphy RM
Protein Eng Des Sel; 2016 Jun; 29(6):209-218. PubMed ID: 27099354
[TBL] [Abstract][Full Text] [Related]
20. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
Lashuel HA; Wurth C; Woo L; Kelly JW
Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
